A medical-device compounder just printed a record quarter — and reported it as a GAAP loss. That gap between the scary headline and the real operations is exactly why the stock jumped 8.47% on June 6 once investors read past the first line.
| Metric | Value |
|---|---|
| Revenue (fiscal Q2 2026) | $1.082B, +8% |
| Organic growth | +5% |
| Non-GAAP diluted EPS | $1.21, up 26% YoY |
| Consensus EPS | $1.10 (beat) |
| GAAP diluted EPS | -$0.40 |
| Earnings beat streak | 10 straight quarters |
| FY2026 EPS guidance | $4.58-$4.66 |
Why it moved
The -$0.40 GAAP loss is a one-off litigation charge tied to the December 2023 CooperSurgical recall. Strip it out and non-GAAP EPS hit $1.21, up 26% and clear of the $1.10 Street estimate — the tenth straight beat. Revenue grew 8% to $1.082B with 5% organic, both CooperVision lenses and CooperSurgical women's health contributing.
What it means for you
Management guided FY2026 revenue to roughly $4.28B-$4.32B and EPS to $4.58-$4.66. The only blemish is an accounting accrual, not the business — and accounting noise is often where patient buyers get a better entry than a clean print would offer.
Bottom line: I'd treat COO as a quality compounder to buy on confusion-driven dips, with two confirmations I want first — organic growth holding above the guide and the litigation overhang fully cleared.